Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMNM NASDAQ:KOD NASDAQ:NRIX NASDAQ:SVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$23.90+1.2%$20.97$7.96▼$27.65$2.67B2.071.69 million shs1.78 million shsKODKodiak Sciences$37.02-3.9%$37.22$3.70▼$47.84$2.41B2.19808,098 shs436,215 shsNRIXNurix Therapeutics$24.04+0.3%$17.85$8.19▼$24.88$2.48B1.83.77 million shs744,359 shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.76N/AN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome0.00%+18.29%+27.07%+9.92%+171.07%KODKodiak Sciences0.00%+7.23%+24.12%-1.18%+873.23%NRIXNurix Therapeutics0.00%+4.72%+63.80%+51.87%+88.37%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$23.90+1.2%$20.97$7.96▼$27.65$2.67B2.071.69 million shs1.78 million shsKODKodiak Sciences$37.02-3.9%$37.22$3.70▼$47.84$2.41B2.19808,098 shs436,215 shsNRIXNurix Therapeutics$24.04+0.3%$17.85$8.19▼$24.88$2.48B1.83.77 million shs744,359 shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.76N/AN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome0.00%+18.29%+27.07%+9.92%+171.07%KODKodiak Sciences0.00%+7.23%+24.12%-1.18%+873.23%NRIXNurix Therapeutics0.00%+4.72%+63.80%+51.87%+88.37%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMNMImmunome 2.85Moderate Buy$33.1738.77% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1413.84% UpsideNRIXNurix Therapeutics 2.81Moderate Buy$32.2033.94% UpsideSVASinovac Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SVA, NRIX, KOD, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026NRIXNurix Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$28.006/18/2026NRIXNurix Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$26.00 ➝ $33.006/15/2026NRIXNurix Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.006/12/2026IMNMImmunome WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$31.006/10/2026NRIXNurix Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.006/9/2026NRIXNurix Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.006/8/2026NRIXNurix Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.006/8/2026NRIXNurix Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold$28.00 ➝ $25.006/8/2026NRIXNurix Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $45.006/8/2026NRIXNurix Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$26.00 ➝ $34.005/28/2026IMNMImmunome Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $37.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMNMImmunome$6.94M390.01N/AN/A$5.75 per share4.16KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ANRIXNurix Therapeutics$83.98M29.60N/AN/A$5.29 per share4.54SVASinovac Biotech$386.01M1.67$0.54 per share11.89$89.01 per share0.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMNMImmunome-$212.39M-$2.38N/AN/AN/AN/A-51.15%-47.32%8/5/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)NRIXNurix Therapeutics-$264.46M-$3.16N/AN/AN/A-411.37%-64.21%-48.44%7/9/2026 (Estimated)SVASinovac Biotech-$59.68MN/AN/AN/AN/AN/AN/AN/A8/13/2026 (Estimated)Latest SVA, NRIX, KOD, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/9/2026Q2 2026NRIXNurix Therapeutics-$0.73N/AN/AN/A$15.29 millionN/A5/12/2026Q1 2026IMNMImmunome-$0.60-$0.48+$0.12-$0.48$0.22 millionN/A5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A4/8/2026Q1 2026NRIXNurix Therapeutics-$0.76-$0.79-$0.03-$0.79$14.25 million$6.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMNMImmunomeN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMNMImmunomeN/A21.6821.68KODKodiak SciencesN/A3.543.54NRIXNurix TherapeuticsN/A6.016.01SVASinovac Biotech0.044.594.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMNMImmunome44.58%KODKodiak Sciences89.06%NRIXNurix TherapeuticsN/ASVASinovac BiotechN/AInsider OwnershipCompanyInsider OwnershipIMNMImmunome7.21%KODKodiak Sciences45.90%NRIXNurix Therapeutics6.70%SVASinovac Biotech12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMNMImmunome40113.25 million105.09 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableNRIXNurix Therapeutics300103.41 million96.48 millionOptionableSVASinovac Biotech3,00899.64 million86.89 millionOptionableSVA, NRIX, KOD, and IMNM HeadlinesRecent News About These CompaniesSinovac Regains Nasdaq Listing Compliance After Filing Delayed Annual ReportJune 15, 2026 | tipranks.comSinovac Biotech Ltd.June 8, 2026 | edition.cnn.comSINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-FJune 5, 2026 | businesswire.comSinovac Faces New Nasdaq Delisting Risk After Regaining ComplianceMay 29, 2026 | tipranks.comSINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual ReportMay 29, 2026 | businesswire.comSVA Share News TodayMay 16, 2026 | uk.investing.comSINOVAC Reports Unaudited First Half of 2025 Financial ResultsMay 8, 2026 | businesswire.comSinovac Biotech Delays Key Annual 20-F FilingApril 30, 2026 | tipranks.comSINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024April 30, 2026 | businesswire.comClearwater Recovery Partners LLP Announces Cash Offer to Purchase Common Shares in Sinovac Biotech Ltd.March 28, 2026 | tennessean.comTSinovac Controlling Shareholders Escape Investor Disclosure SuitFebruary 25, 2026 | news.bloomberglaw.comNSINOVAC Announces Nasdaq Hearings Panel Grants Continued ListingJanuary 22, 2026 | businesswire.comSinovac Biotech receives Nasdaq notification regarding late filing of FY25January 4, 2026 | msn.comSinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year ReportJanuary 4, 2026 | financialpost.comFSINOVAC Provides Update on Antigua High Court Order and Auditor EngagementJanuary 4, 2026 | businesswire.comSinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year ReportJanuary 4, 2026 | businesswire.comAntigua High Court gives Sinovac Biotech board control until trialDecember 17, 2025 | msn.comSinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder MeetingDecember 17, 2025 | caledonianrecord.comCSinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder MeetingDecember 17, 2025 | financialpost.comFSINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to AppealNovember 18, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVA, NRIX, KOD, and IMNM Company DescriptionsImmunome NASDAQ:IMNM$23.90 +0.29 (+1.23%) Closing price 04:00 PM EasternExtended Trading$23.92 +0.02 (+0.06%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Kodiak Sciences NASDAQ:KOD$37.02 -1.52 (-3.94%) Closing price 04:00 PM EasternExtended Trading$38.84 +1.83 (+4.93%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Nurix Therapeutics NASDAQ:NRIX$24.04 +0.07 (+0.29%) Closing price 04:00 PM EasternExtended Trading$23.78 -0.26 (-1.10%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Sinovac Biotech NASDAQ:SVA$6.47 0.00 (0.00%) As of 07/2/2026Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
